- Home
- ICCM vs CCEL Comparison
ICCM vs CCEL Comparison
Compare ICCM & CCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICCM
- CCEL
- Stock Information
- Founded
- ICCM 2006
- CCEL 1989
- Country
- ICCM Israel
- CCEL United States
- Employees
- ICCM N/A
- CCEL N/A
- Industry
- ICCM
- CCEL Managed Health Care
- Sector
- ICCM
- CCEL Health Care
- Exchange
- ICCM Nasdaq
- CCEL Nasdaq
- Market Cap
- ICCM 61.0M
- CCEL 51.9M
- IPO Year
- ICCM N/A
- CCEL 1997
- Fundamental
- Price
- ICCM $1.05
- CCEL $4.97
- Analyst Decision
- ICCM Strong Buy
- CCEL Strong Buy
- Analyst Count
- ICCM 1
- CCEL 1
- Target Price
- ICCM $2.50
- CCEL $8.50
- AVG Volume (30 Days)
- ICCM 254.9K
- CCEL 9.4K
- Earning Date
- ICCM 05-28-2025
- CCEL 07-14-2025
- Dividend Yield
- ICCM N/A
- CCEL 8.05%
- EPS Growth
- ICCM N/A
- CCEL N/A
- EPS
- ICCM N/A
- CCEL 0.01
- Revenue
- ICCM $3,273,000.00
- CCEL $32,102,750.00
- Revenue This Year
- ICCM $85.75
- CCEL $2.49
- Revenue Next Year
- ICCM $189.92
- CCEL $0.95
- P/E Ratio
- ICCM N/A
- CCEL $550.45
- Revenue Growth
- ICCM 0.34
- CCEL 2.33
- 52 Week Low
- ICCM $0.48
- CCEL $4.75
- 52 Week High
- ICCM $1.66
- CCEL $9.43
- Technical
- Relative Strength Index (RSI)
- ICCM 46.97
- CCEL 44.24
- Support Level
- ICCM $0.99
- CCEL $4.79
- Resistance Level
- ICCM $1.14
- CCEL $5.15
- Average True Range (ATR)
- ICCM 0.07
- CCEL 0.17
- MACD
- ICCM 0.01
- CCEL 0.05
- Stochastic Oscillator
- ICCM 64.00
- CCEL 37.93
About ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
About CCEL Cryo-Cell International Inc.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.